This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leyton, J. Articles by Aboagye, E. O. Search for Related Content PubMed PubMed Citation Articles by Leyton, J. Articles by Aboagye, E. O.

Early Detection of Tumor Response to Chemotherapy by 3'-Deoxy-3'-[¹⁸F]Fluorothymidine Positron Emission Tomography: The Effect of Cisplatin on a Fibrosarcoma Tumor Model In vivo

¹ Molecular Therapy Group, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom and ² Department of Oncology, Clinical Research Laboratory, Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden

Requests for reprints: Julius Leyton, Molecular Therapy and PET Oncology Group, Imperial College London, Hammersmith Hospital, Room 240, MRC Cyclotron Building, Du Cane Road, London W12 ONN, United Kingdom. Phone: 0208-383-3798; E-mail: j.leyton{at}ic.ac.uk.

We have assessed the potential of [¹⁸F]fluorothymidine positron emission tomography ([¹⁸F]FLT-PET) to measure early cytostasis and cytotoxicity induced by cisplatin treatment of radiation-induced fibrosarcoma 1 (RIF-1) tumor–bearing mice. Cisplatin-mediated arrest of tumor cell growth and induction of tumor shrinkage at 24 and 48 hours, respectively, were detectable by [¹⁸F]FLT-PET. At 24 and 48 hours, the normalized uptake at 60 minutes (tumor/liver radioactivity ratio at 60 minutes after radiotracer injection; NUV₆₀) for [¹⁸F]FLT was 0.76 ± 0.08 (P = 0.03) and 0.51 ± 0.08 (P = 0.03), respectively, compared with controls (1.02 ± 0.12). The decrease in [¹⁸F]FLT uptake at 24 hours was associated with a decrease in cell proliferation assessed immunohistochemically (a decrease in proliferating cell nuclear antigen labeling index, LI_PCNA, from 14.0 ± 2.0% to 6.2 ± 1.0%; P = 0.001), despite the lack of a change in tumor size. There were G₁-S and G₂-M phase arrests after cisplatin treatment, as determined by cell cycle analysis. For the quantitative measurement of tumor cell proliferation, [¹⁸F]FLT-PET was found to be superior to [¹⁸F]fluorodeoxglucose-PET (NUV₆₀ versus LI_PCNA: r = 0.89, P = 0.001 and r = 0.55, P = 0.06, respectively). At the biochemical level, we found that the changes in [¹⁸F]FLT and [¹⁸F]fluorodeoxglucose uptake were due to changes in levels of thymidine kinase 1 protein, hexokinase, and ATP. This work supports the further development of [¹⁸F]FLT-PET as a generic pharmacodynamic readout for early quantitative imaging of drug-induced changes in cell proliferation in vivo.

This article has been cited by other articles:

				L. Brepoels, S. Stroobants, G. Verhoef, T. De Groot, L. Mortelmans, and C. De Wolf-Peeters 18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model J. Nucl. Med., July 1, 2009; 50(7): 1102 - 1109. [Abstract] [Full Text] [PDF]

				M. P.S. Dunphy and J. S. Lewis Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 106S - 121S. [Abstract] [Full Text] [PDF]

				H.-J. Sohn, Y.-J. Yang, J.-S. Ryu, S. J. Oh, K. C. Im, D. H. Moon, D. H. Lee, C. Suh, J.-S. Lee, and S.-W. Kim [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung Clin. Cancer Res., November 15, 2008; 14(22): 7423 - 7429. [Abstract] [Full Text] [PDF]

				A. K. Buck, M. Bommer, M. E. Juweid, G. Glatting, S. Stilgenbauer, F. M. Mottaghy, M. Schulz, T. Kull, D. Bunjes, P. Moller, et al. First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine J. Nucl. Med., November 1, 2008; 49(11): 1756 - 1762. [Abstract] [Full Text] [PDF]

				J. Leyton, G. Smith, M. Lees, M. Perumal, Q.-d. Nguyen, F. I. Aigbirhio, O. Golovko, Q. He, P. Workman, and E. O. Aboagye Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901 Mol. Cancer Ther., September 1, 2008; 7(9): 3112 - 3121. [Abstract] [Full Text] [PDF]

				J. R. Bading and A. F. Shields Imaging of Cell Proliferation: Status and Prospects J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S. [Abstract] [Full Text] [PDF]

				R. G. Pillai, M. Forster, M. Perumal, F. Mitchell, J. Leyton, F. I. Aibgirhio, O. Golovko, A. L. Jackman, and E. O. Aboagye Imaging Pharmacodynamics of the {alpha}-Folate Receptor-Targeted Thymidylate Synthase Inhibitor BGC 945 Cancer Res., May 15, 2008; 68(10): 3827 - 3834. [Abstract] [Full Text] [PDF]

				A. K. Buck, K. Herrmann, C. M. z. Buschenfelde, M. E. Juweid, M. Bischoff, G. Glatting, G. Weirich, P. Moller, H.-J. Wester, K. Scheidhauer, et al. Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine Clin. Cancer Res., May 15, 2008; 14(10): 2970 - 2977. [Abstract] [Full Text] [PDF]

				M. S. Bradbury, D. Hambardzumyan, P. B. Zanzonico, J. Schwartz, S. Cai, E. M. Burnazi, V. Longo, S. M. Larson, and E. C. Holland Dynamic Small-Animal PET Imaging of Tumor Proliferation with 3'-Deoxy-3'-18F-Fluorothymidine in a Genetically Engineered Mouse Model of High-Grade Gliomas J. Nucl. Med., March 1, 2008; 49(3): 422 - 429. [Abstract] [Full Text] [PDF]

				J. R. Tseng, K. W. Kang, M. Dandekar, S. Yaghoubi, J. H. Lee, J. G. Christensen, S. Muir, P. W. Vincent, N. R. Michaud, and S. S. Gambhir Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by 18F-FDG Small-Animal PET J. Nucl. Med., January 1, 2008; 49(1): 129 - 134. [Abstract] [Full Text] [PDF]

				K. Herrmann, H. A. Wieder, A. K. Buck, M. Schoffel, B.-J. Krause, F. Fend, T. Schuster, C. Meyer zum Buschenfelde, H.-J. Wester, J. Duyster, et al. Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma Clin. Cancer Res., June 15, 2007; 13(12): 3552 - 3558. [Abstract] [Full Text] [PDF]

				E. G.C. Troost, W. V. Vogel, M. A.W. Merkx, P. J. Slootweg, H. A.M. Marres, W. J.M. Peeters, J. Bussink, A. J. van der Kogel, W. J.G. Oyen, and J. H.A.M. Kaanders 18F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients J. Nucl. Med., May 1, 2007; 48(5): 726 - 735. [Abstract] [Full Text] [PDF]

				L. Brepoels, S. Stroobants, P. Vandenberghe, K. Spaepen, P. Dupont, J. Nuyts, G. Bormans, L. Mortelmans, G. Verhoef, and C. De Wolf-Peeters Effect of Corticosteroids on 18F-FDG Uptake in Tumor Lesions After Chemotherapy J. Nucl. Med., March 1, 2007; 48(3): 390 - 397. [Abstract] [Full Text] [PDF]

				A. K. Buck, M. Bommer, S. Stilgenbauer, M. Juweid, G. Glatting, H. Schirrmeister, T. Mattfeldt, D. Tepsic, D. Bunjes, F. M. Mottaghy, et al. Molecular Imaging of Proliferation in Malignant Lymphoma. Cancer Res., November 15, 2006; 66(22): 11055 - 11061. [Abstract] [Full Text] [PDF]

				J. Leyton, M. Lockley, J. L. Aerts, S. K. Baird, E. O. Aboagye, N. R. Lemoine, and I. A. McNeish Quantifying the Activity of Adenoviral E1A CR2 Deletion Mutants Using Renilla Luciferase Bioluminescence and 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Imaging. Cancer Res., September 15, 2006; 66(18): 9178 - 9185. [Abstract] [Full Text] [PDF]

				M. Perumal, R. G. Pillai, H. Barthel, J. Leyton, J. R. Latigo, M. Forster, F. Mitchell, A. L. Jackman, and E. O. Aboagye Redistribution of Nucleoside Transporters to the Cell Membrane Provides a Novel Approach for Imaging Thymidylate Synthase Inhibition by Positron Emission Tomography. Cancer Res., September 1, 2006; 66(17): 8558 - 8564. [Abstract] [Full Text] [PDF]

				J. Leyton, J. P. Alao, M. Da Costa, A. V. Stavropoulou, J. R. Latigo, M. Perumal, R. Pillai, Q. He, P. Atadja, E. W.-F. Lam, et al. In vivo Biological Activity of the Histone Deacetylase Inhibitor LAQ824 Is detectable with 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography. Cancer Res., August 1, 2006; 66(15): 7621 - 7629. [Abstract] [Full Text] [PDF]

				S. Apisarnthanarax, M. M. Alauddin, F. Mourtada, H. Ariga, U. Raju, O. Mawlawi, D. Han, W. G. Bornmann, J. A. Ajani, L. Milas, et al. Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3'-Deoxy-3'-3H-Fluorothymidine Using Preclinical Tumor Models Clin. Cancer Res., August 1, 2006; 12(15): 4590 - 4597. [Abstract] [Full Text] [PDF]

				D. L. Chen and F. Dehdashti Advances in Positron Emission Tomographic Imaging of Lung Cancer Proceedings of the ATS, December 1, 2005; 2(6): 541 - 544. [Abstract] [Full Text] [PDF]

				L. M. Kenny, D. M. Vigushin, A. Al-Nahhas, S. Osman, S. K. Luthra, S. Shousha, R. C. Coombes, and E. O. Aboagye Quantification of Cellular Proliferation in Tumor and Normal Tissues of Patients with Breast Cancer by [18F]Fluorothymidine-Positron Emission Tomography Imaging: Evaluation of Analytical Methods Cancer Res., November 1, 2005; 65(21): 10104 - 10112. [Abstract] [Full Text] [PDF]